Results 31 to 40 of about 22,830 (226)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

EMBO Molecular Medicine, 2023
ROS1 is the largest receptor tyrosine kinase in the human genome. Rearrangements of the ROS1 gene result in oncogenic ROS1 kinase fusion proteins that are currently the only validated biomarkers for targeted therapy with ROS1 TKIs in patients.
Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare   +9 more
doaj   +1 more source

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study

Molecular Oncology, 2023
ROS proto‐oncogene 1, receptor tyrosine kinase (ROS1) rearrangements are a crucial therapeutic target in non‐small cell lung cancer (NSCLC). However, there is limited comprehensive analysis of the molecular patterns of ROS1 fusions.
Shengyu Zhou, Fayan Zhang, Mengxiang Xu, Lei Zhang, Zhengchuang Liu, Qiong Yang, Chunyang Wang, Baoming Wang, Tonghui Ma, Jiao Feng   +9 more
doaj   +1 more source

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. [PDF]

PLoS ONE, 2015
AIMS:To compare fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and quantitative real-time reverse transcription-PCR (qRT-PCR) assays for detection of ROS1 fusion in a large number of ROS1-positive lung adenocatcinoma (ADC) patients.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin   +6 more
doaj   +1 more source

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. [PDF]

PLoS ONE, 2015
To evaluate the frequency and clinicopathological features of ROS1 and RET rearrangements in N2 node positive stage IIIA (IIIA-N2) non-small cell lung cancer (NSCLC) patients, we retrospectively screened 204 cases with a tissue microarray (TMA) panel by ...
Sha Fu, Ying Liang, Yong-Bin Lin, Fang Wang, Ma-Yan Huang, Zi-Chen Zhang, Jing Wang, Wen-Jian Cen, Jian-Yong Shao   +8 more
doaj   +1 more source

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance

npj Precision Oncology, 2023
Patients with ROS1-rearranged NSCLC demonstrate excellent disease control with ROS1-targeted therapy, but acquired resistance is inevitable. Of particular interest is the ROS1 L2086F kinase domain mutation which is refractory to all currently available ...
Mandy Sakamoto, Tejas Patil
doaj   +1 more source

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

, 2022
gene rearrangements occur in 1% to 2% of NSCLC. Acquired “on-target” mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib.
Cui, Wanyuan, Popat, S, Begum, P, Cui, W, Begum, Parvin, Popat, Sanjay   +5 more
core   +1 more source

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma [PDF]

, 2017
PURPOSE: The recent discovery and characterization of an oncogenic ROS1 gene rearrangement has raised significant interest because small molecule inhibitors are effective in these tumors.
박영년, 임선민, 조병철, 유정은   +3 more
core   +1 more source

Is it Time to Implement ROS1 Immunohistochemistry as a Routine Screening Tool in Cases of Nonsmall Cell Lung Cancer? A Study in Indian Population in a Tertiary Care Hospital

CHRISMED Journal of Health and Research
Background: Lung cancer is a leading cause of cancer-related mortality, and nonsmall-cell lung carcinoma (NSCLC) accounts for around 85% of lung cancer cases.
Gurpreet Kaur Walia, Abhishek Singh, Ramanjit Singh Akal   +2 more
doaj   +1 more source

Dual ALK/ROS1 Positivity in Lung Adenocarcinoma: A Case of Complete Response to Lorlatinib

Journal of Oncological Sciences
Objective: Anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) rearrangements are unique, mutually exclusive mutations that drive non-small cell lung cancer.
Neslihan ÖZYURT, Aykut TURHAN
doaj   +1 more source

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

, 2017
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with response to the multitargeted tyrosine kinase inhibitor, crizotinib.
Zhang, Chengsheng, Janne, Pasi, Sholl, Lynette, Sun, Heather, Butaney, Mohit, Lee, Charles, Rodig, Scott   +6 more
core   +1 more source